Antios Therapeutics has been given the cold shoulder by erstwhile development partner Assembly Biosciences (Nasdaq: ASMB), after a clinical hold was placed on its hepatitis B program.
Both firms are working towards finding a curative therapy for hepatitis B, a potentially life-threatening liver infection caused by a virus (HBV).
The short-lived deal, inked in October 2021, saw the firms working together to evaluate a combination of Antios’ lead candidate ATI-2173 and vebicorvir, an HBV core inhibitor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze